Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
BOSTON, March 02, 2023 – Galecto, a clinical-stage biotechnology company focused on fibrosis and cancer treatments, announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference from March 13-15, 2023. Management will present on March 13 at 9:20 am EST and will be available for one-on-one meetings. A live webcast of the presentation can be accessed through Galecto's Investor website, with a replay available after the event.
Galecto's current clinical programs include four Phase 2 trials targeting idiopathic pulmonary fibrosis, myelofibrosis, liver cirrhosis, and non-small cell lung cancer, utilizing various galectin-3 and LOXL2 inhibitors.
- None.
- None.
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1 meetings at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually on March 13-15, 2023. Details for the event are as follows:
| Oppenheimer 33rd Annual Healthcare Conference | |
| Date: | Monday, March 13, 2023 |
| Time: | 9:20 am EST |
| Webcast: | Click Here |
A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website at https://ir.galecto.com/news-and-events/events. A replay of the presentation will be available on this same website following the event.
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a recently completed Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
| Galecto, Inc. | |
| Hans Schambye, CEO Jon Freve, CFO | |
| +45 70 70 52 10 | |
Investors/US | Media/EU |
| Ashley R. Robinson arr@lifesciadvisors.com | Sandya von der Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
FAQ
When is Galecto presenting at the Oppenheimer 33rd Annual Healthcare Conference?
Where can I watch Galecto's presentation at the Oppenheimer Conference?
What are the main clinical programs that Galecto is currently developing?
What is the ticker symbol for Galecto?
What conditions are targeted by Galecto's clinical trials?
